Tirzepatide hmoov CAS 2023788-19-2
|
Parameter |
Paub meej |
|
Khoom npe |
Tirzepatide hmoov |
|
CAS Nr |
2023788-19-2 |
|
Qhov tshwm sim |
Dawb rau tawm -dawb hmoov |
|
Purity (HPLC) |
Ntau dua lossis sib npaug li 98.0% (USP / EP cov qauv) |
|
Cov ntsiab lus Peptide |
Ntau dua lossis sib npaug li 80.0% |
|
Cov ntsiab lus dej |
Tsawg dua lossis sib npaug li 8.0% |
|
Cov ntsiab lus Acetate |
Tsawg dua lossis sib npaug li 12.0% |
|
Endotoxin Qib |
Tsawg dua lossis sib npaug li 50 EU / mg |
Taw qhia ntawm High purity 99% Tirzepatide hmoov
Tirzepatide Powder yog ib qho kev txiav- cov khoom siv tshuaj raw khoom tau los ntawm Tirzepatide (CAS No. 2023788-19-2), ib qho tshiab dual agonist tsom rau Glucose -Dependent Insulinotropic Polypeptide (GIP) thiab Glucagon- Zoo li Peptide-1 (GLPs. Tsim los ntawm Eli Lilly, nws sawv cev rau kev ua tiav hauv kev kho mob ntawm hom 2 mob ntshav qab zib mellitus (T2DM) thiab rog rog, muab cov txiaj ntsig zoo dua piv rau cov tshuaj GLP-1 receptor agonists zoo li Semaglutide hmoov.
Tsis zoo li ib leeg - receptor agonists, Tirzepatide hmoov dual mechanism synergistically txhim khu insulin secretion, suppresses glucagon tso tawm, qeeb plab hnyuv plab, thiab txo qis qab los noj mov, ua rau muaj zog glycemic tswj thiab yuag poob.
Cov Nta Tseem Ceeb & Cov txiaj ntsig ntawm Tirzepatide hmoov
Dual Mechanism of Action
GIP Receptor Activation ntawm Tirzepatide hmoov:
- Txhim kho cov piam thaj -nyob ntawm cov tshuaj insulin tso tawm los ntawm pancreatic -cells.
- Txhim kho lipid metabolism thiab txo cov rog rog rog.
- Modulates cov ntaub so ntswg adipose, txhawb cov rog dawb browning thiab lipolysis.
GLP-1 Receptor Activation ntawm Tirzepatide hmoov:
- Txo glucagon secretion, txo cov ntshav qabzib.
- Ua kom lub plab zom mov qeeb, txo cov khoom noj kom tsawg.
- Activates lub paj hlwb cheeb tsam koom nrog hauv kev cai satiety.
Superior Clinical EfficacyntawmTirzepatide hmoov
Glycemic Control ntawm Tirzepatide hmoov:
- Hauv Phase III kev sim (SURPASS series), Tirzepatide hmoov txo HbA1c los ntawm 2.3–2.6% (15 mg koob), ua haujlwm zoo dua Semaglutide (1.8–2.0%).
- Txog li 60% ntawm cov neeg mob ua tiav HbA1c <7%, piv rau 45% nrog Semaglutide.
Poob Tirzepatide hmoov:
Qhov nruab nrab qhov hnyav ntawm 15-24% (15 mg koob tshuaj ntau tshaj 72 lub lis piam), nrog 35% ntawm cov neeg mob poob ntau dua lossis sib npaug li 25% ntawm lub cev hnyav.
Qhov tseem ceeb tshaj li Semaglutide 15-18% poob phaus hauv kev sim zoo sib xws.
Cardiovascular Protection ntawm Tirzepatide hmoov:
- Txo cov xwm txheej loj ntawm cov hlab plawv (MACE) los ntawm 18% hauv cov neeg mob T2DM.
- Txo cov ntshav siab systolic thiab txhim kho lipid profile.
Ntev -Lub Sij Hawm Kev Nyab XeebntawmTirzepatide hmoov
- Tsis muaj kev pheej hmoo ntawm tus mob pancreatitis lossis thyroid C-cov qog nqaij hlav hauv hlwb tau pom hauv kev sim tshuaj.
- Zoo-tau zam rau cov neeg mob lub raum lossis lub siab tsis zoo.
Technical Specifications
|
Parameter |
Paub meej |
|
Khoom npe |
Tirzepatide hmoov |
|
CAS Nr |
2023788-19-2 |
|
Molecular Formula |
C225 H348 N48 O68 |
|
Molecular Luj |
4813.45 g / mol |
|
Qhov tshwm sim |
Dawb rau tawm -dawb hmoov |
|
Purity (HPLC) |
Ntau dua lossis sib npaug li 98.0% (USP / EP cov qauv) |
|
Cov ntsiab lus Peptide |
Ntau dua lossis sib npaug li 80.0% |
|
Cov ntsiab lus dej |
Tsawg dua lossis sib npaug li 8.0% |
|
Cov ntsiab lus Acetate |
Tsawg dua lossis sib npaug li 12.0% |
|
Endotoxin Qib |
Tsawg dua lossis sib npaug li 50 EU / mg |
|
Solubility |
Soluble nyob rau hauv sterile dej rau txhaj tshuaj (SWFI) los yog bacteriostatic dej |
|
Kev cia khoom |
Khaws ntawm -20℃(lub sijhawm luv: 2–8℃rau Tsawg dua lossis sib npaug li 30 hnub); zam lub teeb thiab khov |
|
Txee lub neej |
24 lub hlis thaum khaws cia zoo |
|
Ntim |
Nqus - kaw vials (1 mg, 5 mg, 10 mg, 100 mg, 1 g) lossis ntau npaum li cas |
Daim Ntawv Thov & Cov Ntawv Qhia Kho Mob ntawm Tirzepatide hmoov
4.1 Pom zoo Siv Tirzepatide hmoov
Hom 2 mob ntshav qab zib mellitus (T2DM):
Raws li kev kho mob monotherapy lossis ua ke nrog metformin, SGLT2 inhibitors, lossis basal insulin.
FDA- pom zoo (2022) thiab EMA- tso cai (2023) rau kev tswj glycemic.
Kev Tswj Obesity:
Qhia rau cov neeg laus uas muaj BMI Ntau dua lossis sib npaug li 30 kg / m² lossis Ntau dua lossis sib npaug li 27 kg / m² nrog comorbidities.
FDA- pom zoo (2023) rau kev tswj qhov hnyav hnyav.
4.2 Kev tshawb nrhiav siv ntawm Tirzepatide hmoov
Tsis yog -Alcoholic Steatohepatitis (NASH):
Kev sim theem III qhia tau tias muaj kev txhim kho daim siab fibrosis thiab steatosis.
Heart Failure with Preserved Ejection Fraction (HFpEF):
Txo cov qib NT-proBNP thiab txhim kho lub peev xwm ua haujlwm.
Pw tsaug zog Apnea & Polycystic Ovary Syndrome (PCOS):
Thaum ntxov- cov kev tshawb fawb theem qhia tau hais tias muaj txiaj ntsig hauv kev txo qis apnea ntu thiab hormonal imbalances.
Tirzepatide hmoov sib piv nrog Semaglutide Powder
|
Parameter |
Tirzepatide hmoov |
Semaglutide hmoov |
|
Receptor Lub Hom Phiaj |
Dual GIP / GLP-1 agonist |
Ib leeg GLP-1 agonist |
|
Kev txo qis HbA1c |
2.3-2.6% (15 mg koob) |
1.5-1.8% (2.4 mg koob) |
|
Poob poob |
15-24% (72 lub lis piam) |
12-18% (68 lub lis piam) |
|
Tus nqi -Kev ua tau zoo |
Tus nqi siab dua tab sis tsawg dua comorbidities |
Tus nqi qis dua tab sis yuav xav tau kev kho mob ntxiv |
Vim Li Cas Xaiv Peb Tirzepatide Powder?
High Purity & Zoo:
Ntau dua lossis sib npaug li 98% purity nrog QC nruj heev.
Customizable Formulations:
Cov tshuaj kho kom haum (1 mg–1 kg) rau R&D lossis siv coj mus muag.
Ntiaj teb no ua raws:
Ua tau raws li USP, EP, thiab ICH cov qauv.
Reliable Supply Chain:
Cov khoom ruaj khov nrog ceev ceev thoob ntiaj teb shipping.
Kev Pabcuam Kws Tshaj Lij:
Kev taw qhia txog kev tsim thiab kev tswj xyuas kev xa tawm.
Tiv tauj peb
Tirzepatide Powder sawv cev rau kev hloov pauv hauv kev tswj ntshav qab zib thiab rog rog, muab cov txiaj ntsig tsis muaj txiaj ntsig los ntawm nws ob GIP / GLP-1 receptor agonism. Nrog cov txiaj ntsig zoo tshaj plaws hauv kev kho mob, qhov kev nyab xeeb zoo, thiab kev siv ntau yam, Tirzepatide Powder tau npaj los ua tus qauv kub hauv kev kho kab mob metabolic.
Rau cov lus nug ntau lossis cov qauv kev cai, hu rau peb pab neeg niaj hnub no kom ruaj ntseg koj cov khoom siv ntawm cov khoom siv tshuaj hloov pauv no.
Email:carine@tnjone.com
Xov tooj:+8618192264745
Txhawb koj txoj kev tshawb fawb thiab kev sim tshuaj nrog rau tiam tom ntej ntawm kev kho mob metabolic.
Cim npe nrov: Tirzepatide hmoov cas 2023788-19-2, Tuam Tshoj tirzepatide hmoov cas 2023788-19-2 manufacturers, lwm tus neeg, Hoobkas
